课题基金 / 基金详情

CLINICAL CENTER FOR TRIALS OF HYPERTENSION PREVENTION

CLINICAL CENTER FOR TRIALS OF HYPERTENSION PREVENTION
高血压预防试验临床中心
批准号:
3552882
负责人:
ALBERT J OBERMAN
金额:
$43.49万
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-09-30 至 1990-06-30

项目摘要

项目成果

ALBERT J OBERMAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This proposal is for Phase 1 of the proposed Trial of Hypertension Prevention, a feasibility study to determine a non-pharmacologic regimen for the prevention of sustained hypertension. A total of 200 men and women with qualifying diastolic blood pressure, 80--94 mmHG at second screening, and ages 25-49 at entry with body weight at least 10% above ideal weight, will be recruited over a nine month period. Eligible participants will be randomly assigned one of four treatment groups; 1) control, 2) weight control, 3) exercise training, or 4) weight control and exercise training. The weight control groups will have the goals of reducing caloric intake and increasing caloric expenditure in order to reduce mean body weight at least 5%. The training groups' goal will be to achieve at least a mean 10% increase in maximal exercise capacity. This Phase 1 feasibility study involves nine months of planning and nine months of recruitment with long-term follow-up of approximately 27 months allowing 3 months for final data analysis and transition to Phase 2 of the study should it be warranted. The primary objectives for this phase of the trial is to test the feasibility of providing and obtaining compliance with the nutritional/exercise interventions, and to measure the short-term effectiveness of the interventions in reducing or preventing an increase in diastolic blood pressure. Final decisions regarding the intervention modality and a common protocol with standard measurements and outcome events would await a common protocol designed by the collaborating clinics as a whole in cooperation with the coordinating center and the National Heart, Lung and Blood Institute.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HYPERGEN
HYPERGEN
HYPERGEN
HYPERGEN